SanBio Yönetim

Yönetim kriter kontrolleri 2/4

SanBio CEO'su Keita Mori, Feb2013 tarihinde atandı, in görev süresi 11.83 yıldır. şirketin hisselerinin 8.74% doğrudan sahiptir ve bu hisselerin değeri ¥ 4.58B dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.9 yıl ve 11.8 yıldır.

Anahtar bilgiler

Keita Mori

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	11.8yrs
CEO sahipliği	8.7%
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	11.8yrs

Son yönetim güncellemeleri

Recent updates

CEO

Keita Mori (57 yo)

11.8yrs

Görev süresi

Mr. Keita Mori, MBA, is a Co-Founder of SanBio, Inc., and served as its Chief Executive Officer and served its Co- Chief Executive Officer since 2001 until October 1, 2018. Mr. Mori has been the President...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kawanishi	Co-Founder & Executive Chairman	11.8yrs	Veri yok	17.81% ¥ 9.3b
Keita Mori	Co-Founder	11.8yrs	Veri yok	8.74% ¥ 4.6b
Yoshihiro Kakutani	Corporate Officer of Management Administration	no data	Veri yok	Veri yok
Naoki Tsukahara	Senior Corporate Officer	3.1yrs	Veri yok	Veri yok
Kazumi Sawaguchi	Corporate Officer and Head of Japan Regulatory Affairs & Quality Compliance Japan	2.9yrs	Veri yok	Veri yok
Keizo Nakada	Corporate Officer & Head of Production	2.4yrs	Veri yok	Veri yok
Shinya Hirata	Corporate Officer & Head of Research and Development	2.3yrs	Veri yok	Veri yok
Dai Chida	Senior Scientific Advisor	no data	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: 4592 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Toru Kawanishi	Co-Founder & Executive Chairman	11.8yrs	Veri yok	17.81% ¥ 9.3b
Keita Mori	Co-Founder	11.8yrs	Veri yok	8.74% ¥ 4.6b
Noboru Kotani	Independent External Director	11.8yrs	Veri yok	0.23% ¥ 120.1m
Yoichi Sato	External Auditor	5.7yrs	Veri yok	Veri yok
Toshimichi Ueda	External Auditor	11.8yrs	Veri yok	0.0092% ¥ 4.8m
Masaaki Tanahashi	External Auditor	6.7yrs	Veri yok	Veri yok

11.8yrs

Ortalama Görev Süresi

59.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 4592 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/28 10:29
Gün Sonu Hisse Fiyatı	2024/12/27 00:00
Kazançlar	2024/10/31
Yıllık Kazançlar	2024/01/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

SanBio Company Limited 12 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Hidemaru Yamaguchi	Citigroup Inc
Miyabi Yamakita	Jefferies LLC
Stephen Barker	Jefferies LLC

SanBio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Co., Ltd. Announces Board Changes

Less than half of directors are independent

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Recent updates

New major risk - Revenue and earnings growth

SanBio Company Limited announced that it expects to receive ¥1.99992672 billion in funding from Athos Capital Limited

SanBio Company Limited Announces the Results of the First Commercial Production Run of AKUUGO

SanBio Company Limited to Report Q3, 2025 Results on Dec 16, 2024

New major risk - Revenue and earnings growth

Sanbio Co., Ltd. Obtains Marketing Approval for AKUUGO Suspension for Intracranial Implantation

SanBio Company Limited to Report Q2, 2025 Results on Sep 17, 2024

Price target increased by 20% to JP¥960

Price target increased by 23% to JP¥983

New major risk - Revenue and earnings growth

SanBio Company Limited Announces Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

SanBio Company Limited to Report Q1, 2025 Results on Jun 13, 2024

New major risk - Revenue and earnings growth

Price target decreased by 30% to JP¥1,214

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

SanBio Company Limited, Annual General Meeting, Apr 24, 2024

Price target increased by 18% to JP¥2,100

Forecast to breakeven in 2027

SanBio Company Limited to Report Fiscal Year 2024 Results on Mar 18, 2024

Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan

New major risk - Financial position

SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

SanBio Company Limited to Report Q3, 2024 Results on Dec 14, 2023

SanBio Company Limited to Report Q2, 2024 Results on Sep 15, 2023

Consensus revenue estimates fall by 15%

SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan

Price target increased by 13% to JP¥2,290

No longer forecast to breakeven

SanBio Company Limited to Report Q1, 2024 Results on Jun 14, 2023

Price target increased by 12% to JP¥2,465

No longer forecast to breakeven

Price target increased by 12% to JP¥2,465

SanBio Company Limited to Report Fiscal Year 2023 Results on Mar 16, 2023

Forecast to breakeven in 2026

SanBio Co., Ltd. Announces Board Changes

SanBio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Less than half of directors are independent

SanBio Company Limited to Report Q3, 2023 Results on Dec 15, 2022

Sanbio Company Limited Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Price target decreased to JP¥2,233

SanBio Company Announces Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury (TBI) Program in Japan

Keizo Nakada to Join Sanbio as Corporate Officer and Head of Production

Price target decreased to JP¥2,200

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2023

SanBio Company Limited Appoints Andrew Liu as Chief Strategy Officer

Less than half of directors are independent

Sanbio Group Provides an Update on One-Year Analysis of the Phase 2 STEMTRA Trial

Sanbio Company Limited Announces Filing with Japan’S Ministry of Health, Labour, and Welfare for Manufacture and Marketing Approval as A Regenerative Medicine Product for the Investigational Product Sb623

Price target increased to JP¥2,900

SanBio Company Limited announced that it expects to receive ¥33.75 million in funding from Nomura Securities Co., Ltd.

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending January 31, 2022

Corporate Officer & Business Head of Japan/Asia Hiroshi Yamamoto has left the company

Price target increased to JP¥2,660

SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

SanBio Company Limited Provides Earnings Guidance for the First Half and Full Year of the Fiscal Year Ending January 31, 2022

Sanbio Company Limited Presents STEMTRA Phase 2 Trial Results At the 44Th Annual Meeting of the Japan Society of Neurotraumatology

SanBio Company Limited to Report Fiscal Year 2021 Results on Mar 17, 2021

SanBio Company Limited Announces Publication of STEMTRA Phase 2 Interim Analysis for SB623 in Neurology

Price target lowered to JP¥2,683

New 90-day low: JP¥1,388

Price target lowered to JP¥2,683

SanBio Company Limited to Report Q3, 2021 Results on Dec 15, 2020

Tokio Marine & Nichido Fire Insurance Co., Ltd. agreed to acquire 9.74% stake in CareNet, Inc. (TSE:2150) from SanBio Company Limited (TSE:4592).

SanBio Company Limited Appoints Hiroyasu Narita as Head of Clinical Development, Effective from October 1, 2020

SanBio Company Limited to Report Q2, 2021 Results on Sep 14, 2020

CEO

Görev süresi

Liderlik Ekibi